Additional file 5: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Figure S3. Kaplan-Meier survival curves for the 58 patients with hypopharyngeal cancer, according to the methylation status of the five target genes. Disease-free survival for (a) SST, (b) TAC1, (c) HCRT, (d) NPY, and (e) GAL in the case of methylated (red lines) and unmethylated (blue lines) genes. (f) Joint analysis of the 5 genes. Blue line: patients with 0–2 methylated genes; red line: patients with 3–5 methylated genes. A probability of < 0.05 (*P < 0.05) was considered to represent a statistically significant difference. (EPS 1460 kb

Additional file 2: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Figure S1. Schematic representation of methylation analysis of 0 on 5 genes by qMSP. Schematic representation of (a) SST, (b) TAC1, (c) HCRT, (d) NPY, and (e) GAL genes. Exon structures and CpG sites within expanded views of the promoter region relative to the transcription start site (TSS). Vertical lines, individual CpG sites; straight arrows, relative location of the primers used for qMSP; bent arrow, TSS; arrowhead, translation start site (ATG). (EPS 1793 kb

Additional file 10: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Figure S8. Methylation and expression status of the five neuropeptide genes in HNSCCs in the TCGA database. Scatter plot analysis for (A) SST, (B) TAC1, (C) HCRT, (D) NPY, and (E) GAL. Spearman rank correlation coefficient (R2) and P values are shown. (EPS 2568 kb

Additional file 3: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Figure S2. ROC curves for the methylation markers in head and neck carcinomas versus adjacent normal mucosal tissue. On the basis of the ROC curve analysis, the sensitivity, specificity, and cutoff level were determined to be 80.6%, 94.4%, and 0.046 for SST (a); 72.2%, 97.2%, and 0.08 for TAC1 (b); 67.6%, 97.2%, and 0.099 for HCRT (c); 50.0%, 97.2%, and 0.041 for NPY (d); and 25.0%, 86.1%, and 0.100 for GAL (e). (EPS 1057 kb

Additional file 4: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Table S2. Results of log-rank tests for the effect of number of methylated genes on disease-free survival in 230 HNSCC cases. (DOCX 14 kb

Additional file 11: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Table S3. Distribution of methylation status by recurrence events in TCGA cohort. (DOCX 17 kb

Additional file 1: of The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Table S1. Real-time MSP primer list. (DOCX 20 kb